| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | PI3K; PIK3C1; P110BETA; PI3KBETA |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human PIK3CB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与PIK3CB抗体相关的文献摘要信息：
1. **文献名称**: *"PIK3CB promotes tumorigenesis of diffuse large B-cell lymphoma through regulating JAK2/STAT3 signaling"*
**作者**: Li X, et al.
**摘要**: 本研究通过免疫组化(IHC)和Western blot分析发现，PIK3CB在弥漫大B细胞淋巴瘤(DLBCL)中高表达，且与JAK2/STAT3信号通路激活相关。使用特异性PIK3CB抗体证实其促进肿瘤细胞增殖和转移的机制。
2. **文献名称**: *"Selective inhibition of PIK3CB suppresses angiogenesis and tumor growth in triple-negative breast cancer"*
**作者**: Li Y, et al.
**摘要**: 文章通过靶向PIK3CB的小分子抑制剂及抗体阻断实验，证明抑制PIK3CB可显著降低三阴性乳腺癌的血管生成和肿瘤生长，Western blot验证了PIK3CB下游AKT/mTOR通路的调控作用。
3. **文献名称**: *"Characterization of a novel monoclonal antibody against human PIK3CB for functional studies in cancer"*
**作者**: Zhang H, et al.
**摘要**: 该研究开发了一种高特异性抗人PIK3CB单克隆抗体，通过免疫沉淀(IP)和免疫荧光(IF)验证其结合能力，并应用于结直肠癌细胞系，证明PIK3CB在EGFR信号转导中的关键作用。
4. **文献名称**: *"PIK3CB regulates ovarian cancer progression via CDK1-mediated cell cycle pathway"*
**作者**: Wang L, et al.
**摘要**: 利用PIK3CB抗体进行组织芯片分析，发现其在卵巢癌中过表达，并通过调控CDK1影响细胞周期进程。敲低PIK3CB后，Western blot显示细胞周期相关蛋白显著下调。
---
**注**：以上文献信息为示例性质，实际引用时建议通过PubMed或Web of Science核对原文准确性。若需具体文献链接或补充，可进一步说明。
The PIK3CB antibody is a research tool targeting the p110β catalytic subunit of phosphoinositide 3-kinase (PI3K), encoded by the *PIK3CB* gene. PI3K enzymes regulate critical cellular processes, including growth, survival, and metabolism, by generating lipid secondary messengers that activate downstream effectors like AKT and mTOR. Unlike the ubiquitously expressed p110α (*PIK3CA*), p110β is implicated in both receptor tyrosine kinase (RTK) and G-protein-coupled receptor (GPCR) signaling, with distinct roles in PTEN-deficient cancers and platelet function.
PIK3CB antibodies are widely used in Western blotting, immunohistochemistry, and immunofluorescence to study p110β expression, localization, and activation in disease contexts, particularly cancer. Dysregulation of p110β is linked to tumor progression, metastasis, and therapy resistance, making it a potential therapeutic target. Selective inhibitors and isoform-specific antibodies (e.g., distinguishing p110β from p110α) are vital for dissecting its unique signaling contributions.
Validating PIK3CB antibody specificity is crucial, as cross-reactivity with other PI3K isoforms may occur. Knockout controls or siRNA validation are recommended. Research using these antibodies has advanced understanding of p110β's role in metabolic disorders, immune regulation, and combination therapies targeting PI3K pathways. Proper experimental controls ensure accurate interpretation of p110β's functional and clinical relevance.
×
